FDA approved a supplemental biologics license application for Gazyva

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved a supplemental biologics license application for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia.

The sBLA adds to the label data from Stage 2 of the phase III CLL11 study showing significant improvements with Gazyva plus chlorambucil across multiple clinical endpoints when compared head-to-head with Rituxan (rituximab) plus chlorambucil.

The approval includes complete response and minimal residual disease data from the study. Additionally, overall survival data was added from Stage 1 of the study comparing Gazyva plus chlorambucil to chlorambucil alone. Gazyva is sponsored by Genentech, a member of the Roche Group.

The sBLA approval updated the Gazyva prescribing information with the following data: Gazyva plus chlorambucil helped people with previously untreated CLL live nearly a year longer without their disease worsening or death than Rituxan plus chlorambucil (median PFS: 26.7 months vs. 14.9 months, respectively. HR=0.42, 95 percent CI 0.33-0.54, p<0.0001); and that Gazyva plus chlorambucil nearly tripled the number of people showing no evidence of disease compared to Rituxan plus chlorambucil (26.1 percent vs. 8.8 percent, respectively).

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login